Structural analysis of the range of group r06a antihistamines for systemic use

Abstract

The high prevalence and steady increase in the frequency of allergic diseases worldwide place the problem of treatment and prevention of patients in this group among the most urgent problems of health care. Such prevalence of morbidity is associated with an unfavourable environmental situation, heredity, unfavourable living conditions, unhealthy diet, uncontrolled use of medications. Accordingly, the use of antihistamine drugs (ADs) significantly improves the quality of life of patients by eliminating the symptoms of various allergic diseases, in particular allergic rhinitis, allergic conjunctivitis, urticaria and even allergic asthma; prevention of allergic reactions; prevention of the development of severe allergic reactions, such as Quincke's edema. Thus, the modern pharmaceutical market offers ADs for the treatment of various manifestations of allergies, and the variety of dosage forms creates favourable conditions for choosing the optimal drug depending on the clinical form of allergy